|
EP2146967A2
|
|
Tetrahydroindole and tetrahydroindazole derivatives
|
|
WO2008045529A1
|
|
Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
|
|
WO2008024970A2
|
|
Tetrahydroindolone and tetrahydroindazolone derivatives
|
|
WO2008024961A1
|
|
Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat-shock protein 90 inhibitors
|
|
WO2008024981A1
|
|
Piperazine-substituted benzothiophenes for treatment of mental disorders
|
|
US2008119457A1
|
|
Benzene, Pyridine, and Pyridazine Derivatives
|
|
US2008070935A1
|
|
Quinazoline derivatives for the treatment of cancer
|
|
MY143583A
|
|
Tetrahydroindolone and tetrahydroindazolone derivatives
|
|
WO2008024974A1
|
|
Pyrimidine and pyrazine derivatives
|
|
WO2008024963A1
|
|
Benzene, pyridine, and pyridazine derivatives
|
|
WO2007147133A1
|
|
Stabilized tetracycline compositions
|
|
WO2007147125A2
|
|
Tetracycline package formulations
|
|
EP1991525A1
|
|
Cyclohexylamino, benzene, pyridine, and pyridazine derivatives
|
|
WO2007090032A2
|
|
Ribosomal protein s6 as a pharmacodynamic marker for hsp90 inhibition
|
|
CN101268048A
|
|
Carbazole derivatives
|
|
UA92907C2
|
|
Tetrahydroindazolone derivatives
|
|
AP200704125A0
|
|
Tetrahydroindolone and tetrahydroindazolone derivatives
|
|
US2006074105A1
|
|
Substituted quinoline and quinazoline inhibitors of quinone reductase 2
|
|
CA2575571A1
|
|
2,8-disubstituted naphthyridine derivatives
|
|
US2006035901A1
|
|
Methotrexate derivatives useful for treating cancer and arthritis
|
